169 |
Inflammation: Novel Target for Cardiovascular Risk Reduction |
Andrew Zalewski |
Sep. 23. 05 |
168 |
Mechanisms Linking Angiotensin II & Atherogenesis |
Carlos M. Ferrario |
Sep. 23. 05 |
167 |
Beyond the Statin Therapy: The Importance of HDL Cholesterol |
Ki Hoon Han |
Sep. 23. 05 |
166 |
Early Statin Therapy in Acute Coronary Syndrome |
Cheol Whan Lee |
Sep. 23. 05 |
165 |
The TNT Trial: Is It Time to Shift Our Goals in Clinical Practice |
David Colquhoun |
Sep. 23. 05 |
164 |
Is Sirolimus Different from Analogues? |
Robert Falotico |
Sep. 14. 05 |
163 |
Safety and Efficacy of Cypher on Complex Lesion |
Seung-Jung Park |
Sep. 14. 05 |
162 |
REALITY Head-To-Head Comparison |
Alexandre Abizaid |
Sep. 14. 05 |
161 |
Safety and Endeavor II Subsets |
Richard E. Kuntz |
Sep. 14. 05 |
160 |
Overview of Endeavor II Clinical Results |
Ian T. Meredith |
Sep. 14. 05 |